ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / UTMD / insiders
KTWO (56) PROF (40) PDEX (54) OSUR (31) ⌘ Pro Terminal →

Utah Medical Products Inc. (UTMD) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$70.55 +3.64% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $70.88

Utah Medical Products Inc. (UTMD) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $216.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on UTMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is UTMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Utah Medical Products Inc. (NASDAQ: UTMD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $70.55 (+3.64% 1D, market cap $216.7M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, UTMD ranks #152 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does UTMD compare to KTWO and PROF in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), UTMD carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of 57.1%, and ROIC of 26.9%. By comparison, KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) holds a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $202.2M) and PROF (Profound Medical Corp.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $240.0M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for UTMD?
▼

Per UTMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000706698), Utah Medical Products Inc. generated $38.5M in revenue (-5.8% YoY), $0 in net income, and $14.3M in free cash flow against $122.5M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (57.1% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $70.88 (+0.47%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 37.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510062
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk C-
Cash (17)Whales (6)SEC (13)Macro (11)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+1.8% Base Target
$85 Bull$72 Base$56 Bear
📬 FREE UTMD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for UTMD)Realized 20D OHLCV Swing Band: ±4%
Deterministic 5-Pillar Attribution (62/100 Composite)
🔍 WHY UTMD SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+17/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 37.2% FCF Margin ($14.3M FCF) & 57.1% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
70
Grade B$74.71+0.5% Next Q
Q2 (-2Q)
67
Grade B-$75.07-2.7% Next Q
Q3 (-1Q)
65
Grade C+$73.06-3.4% Next Q
Current
62
Grade C$70.55+0.7% Hist 90D α
Trajectory: B (70) → C (62)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the UTMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 62/100 (C) score, UTMD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 54.6% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($72.73) or 200D SMA ($68.14) invalidates the momentum regime and cuts Target Base ($71.82) toward Bear Floor ($56.02).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $UTMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “UTMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 62%NO 38%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

UTMD Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (UTMD)

No recent open-market Form 4 cluster sales or emergency dumps flagged on UTMD. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (UTMD Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
UTMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +9.13%📐 HORIZONTAL RANGE
2026-11-03O $66.81H $70.55L $66.81C $70.55VOL 42.8K
RES: $78.50SUP: $66.50SMA50: $72.73SMA200: $68.14
$78.01$73.38$68.75$64.12$59.49RES $78.50SUP $66.50$70.552026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

UTMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 UTMD Butterfly Map → + Track UTMD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
5.0%/yr Implied 5Y Growth

vs. -5.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on UTMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for UTMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for UTMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (UTMD)

Health Care Rank #152 of 1015 ⚔️ KTWO vs UTMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (UTMD vs. KTWO, PROF, PDEX, OSUR)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Utah Medical Products Inc. (UTMD) ranks #152 by composite RQD confidence (62/100, grade C) and #561 by equity capitalization ($216.7M). Within this direct 5-issuer industry benchmark cohort, PDEX leads on earnings valuation at 22.2x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. UTMD currently leads its immediate peer cohort in composite quantitative strength at 62/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
UTMD ACTIVE
Utah Medical Products Inc.
C 62/100 — 57.1% 26.9% +3.64% $216.7M Benchmark Subject
KTWO
K2 Capital Acquisition Corporation Class A Ordinary Share
D+ 56/100 — — — +0.20% $202.2M /ktwo-vs-utmd →
PROF
Profound Medical Corp.
D- 40/100 — 70.8% -35.0% +2.44% $240.0M /prof-vs-utmd →
PDEX
Pro-Dex Inc.
D+ 54/100 22.2x 29.3% 23.2% -0.88% $186.1M /pdex-vs-utmd →
OSUR
OraSure Technologies Inc.
E 31/100 — 41.9% -35.0% -12.31% $271.7M /osur-vs-utmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000706698 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Utah Medical Products Inc. (UTMD) reported GAAP revenue of $38.5M (-5.8% vs. FY2024 revenue of $40.9M , and -23.3% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $14.7M, and free cash flow of $14.3M (-1.9% YoY). On the balance sheet, UTMD closed FY2025 with $122.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $38.5M $0 $14.7M $14.3M $122.5M —
FY2024 (FY) 2024-12-31 $40.9M $0 $14.8M $14.6M $122.5M —
FY2023 (FY) 2023-12-31 $50.2M $0 $22.3M $22.3M — —

3. UTMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is UTMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Utah Medical Products Inc. (NASDAQ: UTMD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $70.55 (+3.64% 1D, market cap $216.7M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, UTMD ranks #152 in composite RQD confidence.

How does UTMD compare to KTWO and PROF in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), UTMD carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of 57.1%, and ROIC of 26.9%. By comparison, KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) holds a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $202.2M) and PROF (Profound Medical Corp.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $240.0M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for UTMD?

Per UTMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000706698), Utah Medical Products Inc. generated $38.5M in revenue (-5.8% YoY), $0 in net income, and $14.3M in free cash flow against $122.5M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (57.1% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is UTMD trading relative to its 50-day, 200-day, and 52-week technical levels?

UTMD last traded at $70.55 (+3.64% on volume of 38,991 shares), positioning the stock -3.00% below its 50-day simple moving average ($72.73) and +3.54% above its 200-day simple moving average ($68.14). Across its 52-week range of $53.66 to $76.89, UTMD sits at the 72.7% percentile with a 14-day RSI of 34.2 (NEUTRAL RANGE) and an implied next-earnings move of ±4.0% ($67.73 to $73.37).

Direct Sub-Reports: UTMD RQD Cockpit UTMD 12M Forecast UTMD Earnings & Move UTMD Dividends & DRIP UTMD Insiders & 13F UTMD Whale Options UTMD Profit Sankey UTMD News & Why
ROARABLE RATING BRIEF • RQD 62/100 (C) ✓ SEC XBRL & RQD VERIFIED

UTMD — Utah Medical Products Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Utah Medical Products Inc. (UTMD) earns a live Roarable RQD composite score of 62/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $70.55 (+3.64% 1D, market capitalization $216.7M).

  • Fundamental Cash Engine (17/20): Anchored by return on invested capital (ROIC) of 26.9%, gross margin of 57.1%, operating margin of 29.6%, and free cash flow yield of 6.73%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (UTMD) is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry, with a market capitalization of $0.2B. Per the market data, the company reports a gross margin of 57.1% and an operating margin of 29.6%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Utah Medical Products Inc. (UTMD) reported $38.5M in annual revenue (up from $40.9M in FY2024, -5.8% YoY) and $0 in GAAP net income. Over the multi-year SEC filing window from FY2023 ($50.2M revenue, $0 net income) through FY2025, UTMD scaled operating cash flow to $14.7M and free cash flow to $14.3M, backed by $122.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C • RQD 62/100): Strong cash generator (57.1% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 17/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $53.66 – $76.89 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh current valuation and 10.8x EV/EBITDA against 29.6% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector is Health Care and industry is Medical/Dental Instruments. No upstream or downstream dependencies, sector correlations, or second-order bottlenecks are identified in the source data.

  • Key Question #1: Can UTMD sustain or expand its 29.6% operating margin and 26.9% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $38.5M and free cash flow of $14.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is UTMD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

UTMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Utah Medical Products Inc. (UTMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to UTMD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

UTMD Bull vs. Bear Conversation Board — What's Your Call at $70.55?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON UTMD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on UTMD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $81.70 (+20.0%)
📌 Pinned Debate

ROIC of 26.9% and a 6.73% FCF yield indicate a highly capital-efficient cash engine trading at 10.8x EV/EBITDA.

Long UTMD at $68.08 targeting $81.70. ROIC of 26.9% and a 6.73% FCF yield indicate a highly capital-efficient cash engine trading at 10.8x EV/EBITDA.. Institutional whale score is 6/20 and the risk/reward vs. the $53.66 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

Both sides have a point here — UTMD's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $52.42 (-23.0%)
Spot @ $68.08

Revenue fell from $50.2M to $38.5M over two years and net margin is 0%, while institutional flow scores only 6 of 20.

I respect the product at Utah Medical Products Inc., but the stock at $68.08 is a different story. Revenue fell from $50.2M to $38.5M over two years and net margin is 0%, while institutional flow scores only 6 of 20.. FCF yield is 6.73% and RQD sits at 62/100 (C) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%